• TRADE NAME: Tavalisse (Rigel)
• INDICATIONS: Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment
  
• CLASS: Spleen tyrosine kinase (Syk) inhibitor
• HALF-LIFE: ~15 hours

• FDA APPROVAL DATE: 04/17/2018
• CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
  Strong CYP3A4 inhibitors or inducers
• PREGNANCY: Based on animal studies, can cause fetal harm

DRUG REVIEW ARTICLE

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fostamatinib in the Taylor & Francis journal Expert Opinion on Drug Safety.

(Note that non-subscribers to the journal will only be able to see an abstract of the article.)